HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...

Introduction Maximising the impact of new and forthcoming long-acting injectable HIV pre-exposure prophylaxis (PrEP) products ...

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

CVS is now covering long-acting injectable PrEP, representing a shift from last year when the pharmacy giant announced it was not yet moving forward with that ...

The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an injectable form of the HIV prevention medication known as PrEP, marking a ...

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully passed an important early safety trial. Researchers have shared that the drug ...

Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden administration announced October 21. The news comes just weeks after it was announced ...

Please provide your email address to receive an email when new articles are posted on . Among nearly 2,500 women, almost 80% chose long-acting, injectable cabotegravir for HIV PrEP. Reasons included ...

HOUSTON — The fight against HIV has come a long way, and new advancements in prevention are changing the game. One of the latest breakthroughs is a long-lasting injectable form of PrEP (pre-exposure ...

A recent study has found that lenacapavir, an injectable medication administered twice a year, is more effective at preventing HIV among gay, bisexual, and transgender people than a daily regimen of ...